trending Market Intelligence /marketintelligence/en/news-insights/trending/P7q3s5ys6_1oIU8kturqeQ2 content esgSubNav
In This List

Novartis' Extavia approved by UK NICE for MS treatment; Teva's Copaxone rejected

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Novartis' Extavia approved by UK NICE for MS treatment; Teva's Copaxone rejected

The U.K. National Institute for Health and Care Excellence recommended Novartis AG's Extavia for treating multiple sclerosis, or MS, under certain conditions.

The regulator said in draft guidelines that it does not recommend certain other beta interferon MS treatments because of cost concerns, namely Teva Pharmaceutical Industries Ltd.'s Copaxone, Biogen Inc.'s Avonex and Plegridy, Bayer AG's Betaferon and Merck Serono S.A.'s Rebif. The guidance said Extavia is more cost-effective than the other treatments.

NICE recommended Extavia for use under the National Health Service for patients who have relapsing–remitting MS or patients who have secondary progressive MS with continued relapses. The drug is recommended only if Novartis provides the discount agreed upon in the patient access scheme.

The closing date for comments on the guidance is Jan. 24, 2018.

MS is a potentially disabling disease that affects the brain and the spinal cord. Extavia is also approved by the U.S. Food and Drug Administration.